Home » news »

Subcutaneous exendin treats post-bariatric hypoglycemia

 

(HealthDay)—Subcutaneous exendin (SC Ex-9) appears to be protected and effective in treating post-bariatric hypoglycemia (PBH), according to a investigate published online Aug. 4 in Diabetes, Obesity and Metabolism.

Colleen M. Craig, M.D., from a Stanford University School of Medicine in California, and colleagues conducted a initial in-human subcutaneous administration of Ex-9 in 9 womanlike patients with PBH following Roux-en-Y gastric bypass. First, a singular member underwent equimolar low-dose IV contra subcutaneous Ex-9 administration. Then, 8 participants were administered singular descending doses of SC Ex-9 during verbal glucose tolerance testing.

The researchers celebrated an exposure-response relationship, though all doses effectively prevented hyperinsulinemic hypoglycemia and softened compared symptoms. The postprandial glucose underside was increasing by 66 percent, rise insulin was reduced by 57 percent, and neuroglycopenic symptoms were reduced by 80 percent, on average. No treatment-related inauspicious events were reported.

“SC Ex-9 appears to paint a safe, effective, and targeted healing proceed for diagnosis of PBH,” a authors write. “Further review involving mixed doses with ongoing dosing is warranted.”

Several authors disclosed financial ties to a curative industry.


Explore further:
Similar defects ID’d for T2DM, ongoing pancreatitis and diabetes

More information:
Abstract
Full Text (subscription or remuneration might be required)

feedback
feedback to editors

 

Related Posts

  • No Related Posts